EGFR and non-small cell lung carcinoma: In January 2022, ABBV‐399 was granted breakthrough therapy designation by the US FDA for the treatment of advanced or metastatic MET overexpressing EGFR WT nonsquamous NSCLC patients who have progressed after platinum‐based therapy.